Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device: Phase 2 Data to 36 Months

Reproductive Health

Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System

Obstet Gynecol.

Teal SB, Turok DK, Chen BA, Kimble T, Olariu AI, Creinin MD

doi: 10.1097/AOG.

Overactive Bladder

Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial

Urology.

Chen H, Wang F, Yu Z, Zhang Y, Liu C, Dai S, Chen B, Lv J

doi: 10.1016/j.urology.2016.11.008.

Reproductive Health

Effectiveness and Safety of Extending Intrauterine Device Duration: A Systematic Review

Am J Obstet Gynecol.

Ti AJ, Roe AH, Whitehouse KC, Smith RA, Gaffield ME, Curtis KM

doi: 10.1016/j.ajog.2020.01.014.

HPV and Gynecologic Cancer

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer

Am J Obstet Gynecol.

Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS

doi: 10.1016/j.ajog.2020.08.032.

Menopause

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review

Menopause.

Constantine GD, Graham S, Lapane K, Ohleth K, Bernick B, Liu J, Mirkin S

doi: 10.1097/GME.

Reproductive Health

Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial

Hum Reprod.

Saunders H, Khan C, D'Hooghe T, Magnúsdóttir TB, Klingmann I, Hrafnsdóttir S, vaginal progesterone luteal phase support post IVF study group.

doi: 10.1093/humrep/dez261.

Overactive Bladder

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)

Eur Urol.

Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR

doi: 10.1016/j.eururo.2019.10.002.

Overactive Bladder

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)

Eur Urol.

Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER

doi: 10.1016/j.eururo.

Overactive BladderUrinary Tract Infections (UTI)

Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial

Lancet Infect Dis.

Fisher H, Oluboyede Y, Chadwick T, Abdel-Fattah M, Brennand C, Fader M, Harrison S, Hilton P, Larcombe J, Little P, McClurg D, McColl E, N'Dow J, Ternent L, Thiruchelvam N, Timoney A, Vale L, Walton K, von Wilamowitz-Moellendorff A, Wilkinson J, Wood R, Pickard R

doi: 10.1016/S1473-3099

Related content

Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System

Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial

Effectiveness and Safety of Extending Intrauterine Device Duration: A Systematic Review

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review

Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)

Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial